Y. Joseph Woo

Dr. Y. Joseph Woo


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
AGAndrew B. Goldstone
Andrew B. Goldstone
PCPeter Chiu
Peter Chiu
MBMichael Baiocchi
Michael Baiocchi
BLBharathi Lingala
Bharathi Lingala
WPWilliam L. Patrick
William L. Patrick
YWY. Joseph Woo
Y. Joseph Woo
In patients undergoing aortic-valve or mitral-valve replacement, either a mechanical or biologic prosthesis is used. Biologic prostheses have been increasingly favored despite limited evidence supporting this practice.

1 October 2020 in JACC
Verified
Journal Article
Closed access
YZYuanjia Zhu
Yuanjia Zhu
BLBharathi Lingala
Bharathi Lingala
MBMichael Baiocchi
Michael Baiocchi
JTJacqueline J. Tao
Jacqueline J. Tao
VAVeronica Toro Arana
Veronica Toro Arana
YWY. Joseph Woo
Y. Joseph Woo

7 August 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
LSLyndsay M. Stapleton
Lyndsay M. Stapleton
ASAmanda N. Steele
Amanda N. Steele
HWHanjay Wang
Hanjay Wang
HHHector Lopez Hernandez
Hector Lopez Hernandez
AYAnthony C. Yu
Anthony C. Yu
YWY. Joseph Woo
Y. Joseph Woo

1 February 2019 in Cell
Verified
Journal Article
Closed access
SDSoumyashree Das
Soumyashree Das
AGAndrew B. Goldstone
Andrew B. Goldstone
HWHanjay Wang
Hanjay Wang
JFJustin Farry
Justin Farry
GDGaetano D’aMato
Gaetano D’aMato
KRKristy Red-Horse
Kristy Red-Horse

2 June 2017 in Science Advances
Verified
Journal Article
Open access
PDF file
JCJeffrey E. Cohen
Jeffrey E. Cohen
AGAndrew B. Goldstone
Andrew B. Goldstone
MPMichael Paulsen
Michael Paulsen
YSYasuhiro Shudo
Yasuhiro Shudo
ASAmanda N. Steele
Amanda N. Steele
YWY. Joseph Woo
Y. Joseph Woo
Coronary artery disease is one of the most common causes of death and disability, afflicting more than 15 million Americans. Although pharmacological advances and revascularization techniques have decreased mortality, many survivors will eventually succumb to heart failure secondary to the residual microvascular perfusion deficit that remains after revascularization. We present a novel system that rescues the myocardium from acute ischemia, using photosynthesis through intramyocardial delivery of the cyanobacterium Synechococcus elongatus. By using light rather than blood flow as a source of energy, photosynthetic therapy increases tissue oxygenation, maintains myocardial metabolism, and yields durable improvements in cardiac function during and after induction of ischemia. By circumventing blood flow entirely to provide tissue with oxygen and nutrients, this system has the potential to create a paradigm shift in the way ischemic heart disease is treated.

18 April 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
RCRoshni Roy Chowdhury
Roshni Roy Chowdhury
JDJessica D’addabbo
Jessica D’addabbo
XHXianxi Huang
Xianxi Huang
SVStefan Veizades
Stefan Veizades
KSKoki Sasagawa
Koki Sasagawa
Patricia NguyenPatricia Nguyen
Patricia Nguyen
Background: Coronary artery disease is an incurable, life-threatening disease that was once considered primarily a disorder of lipid deposition. Coronary artery disease is now also characterized by chronic inflammation‚ notable for the buildup of atherosclerotic plaques containing immune cells in various states of activation and differentiation. Understanding how these immune cells contribute to disease progression may lead to the development of novel therapeutic strategies. Methods: We used single-cell technology and in vitro assays to interrogate the immune microenvironment of human coronary atherosclerotic plaque at different stages of maturity. Results: In addition to macrophages, we found a high proportion of αβ T cells in the coronary plaques. Most of these T cells lack high expression of CCR7 and L-selectin , indicating that they are primarily antigen-experienced memory cells. Notably, nearly one-third of these cells express the HLA-DRA surface marker, signifying activation through their TCRs (T-cell receptors). Consistent with this, TCR repertoire analysis confirmed the presence of activated αβ T cells (CD4<CD8), exhibiting clonal expansion of specific TCRs. Interestingly, we found that these plaque T cells had TCRs specific for influenza, coronavirus, and other viral epitopes, which share sequence homologies to proteins found on smooth muscle cells and endothelial cells, suggesting potential autoimmune-mediated T-cell activation in the absence of active infection. To better understand the potential function of these activated plaque T cells, we then interrogated their transcriptome at the single-cell level. Of the 3 T-cell phenotypic clusters with the highest expression of the activation marker HLA-DRA , 2 clusters expressed a proinflammatory and cytolytic signature characteristic of CD8 cells, while the other expressed AREG (amphiregulin), which promotes smooth muscle cell proliferation and fibrosis, and, thus, contributes to plaque progression. Conclusions: Taken together, these findings demonstrate that plaque T cells are clonally expanded potentially by antigen engagement, are potentially reactive to self-epitopes, and may interact with smooth muscle cells and macrophages in the plaque microenvironment.